InsiderSignal.AI

InsiderSignal.ai

OABI - Omniab, Inc.

Insider Sale by Foehr Matthew W (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Foehr Matthew W, serving as Pres, CEO at Omniab, Inc. (OABI), sold 19,244 shares at $1.49 per share, for a total transaction value of $28,674.00. Following this transaction, Foehr Matthew W now holds 4,420,492 shares of OABI.

The trade was executed on Tuesday, April 7, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, April 7, 2026, meaning the disclosure happened on the same day as the trade.

Omniab, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Foehr Matthew W

Pres, CEO

Matthew W. Foehr is an independent director on the board of Viking Therapeutics, Inc. (VKTX), serving since May 2014.[[1]](https://fintool.com/app/research/companies/VKTX/people/matthew-foehr)[[2]](https://investors.omniab.com/investors/governance/board-of-directors/person-details/default.aspx?ItemId=8148bd5e-1436-41db-a4dd-d8da627b7e85)[[5]](https://www.itiger.com/stock/VKTX/company) Aged 52, he brings over 25 years of experience in pharmaceutical operations, R&D, manufacturing, and integration.[[1]](https://fintool.com/app/research/companies/VKTX/people/matthew-foehr)[[2]](https://investors.omniab.com/investors/governance/board-of-directors/person-details/default.aspx?ItemId=8148bd5e-1436-41db-a4dd-d8da627b7e85) Foehr currently serves as President, CEO, and Director of OmniAb, Inc. since November 2022.[[1]](https://fintool.com/app/research/companies/VKTX/people/matthew-foehr)[[2]](https://investors.omniab.com/investors/governance/board-of-directors/person-details/default.aspx?ItemId=8148bd5e-1436-41db-a4dd-d8da627b7e85)[[6]](https://investors.omniab.com/investors/governance/executive-management/default.aspx)[[7]](https://www.marketscreener.com/insider/MATTHEW-FOEHR-A00TBB/) His career highlights include roles as President and COO at Ligand Pharmaceuticals (2015–2022), EVP and COO at Ligand (2011–2015), VP and Head of Consumer Dermatology R&D at GSK's Stiefel division (2010–2011) where he led post-acquisition R&D integration, and senior positions at Stiefel Laboratories, Connetics Corporation, LXR Biotechnology, and Berlex Biosciences.[[1]](https://fintool.com/app/research/companies/VKTX/people/matthew-foehr)[[2]](https://investors.omniab.com/investors/governance/board-of-directors/person-details/default.aspx?ItemId=8148bd5e-1436-41db-a4dd-d8da627b7e85) He previously served on the board of Ritter Pharmaceuticals (2015–2020).[[1]](https://fintool.com/app/research/companies/VKTX/people/matthew-foehr)[[2]](https://investors.omniab.com/investors/governance/board-of-directors/person-details/default.aspx?ItemId=8148bd5e-1436-41db-a4dd-d8da627b7e85)[[4]](https://www.sec.gov/Archives/edgar/data/886163/000088616315000011/lgndfoehrnamedpresident.htm) Foehr holds a BS in Biology from Santa Clara University and is the author of multiple scientific publications.[[1]](https://fintool.com/app/research/companies/VKTX/people/matthew-foehr)[[2]](https://investors.omniab.com/investors/governance/board-of-directors/person-details/default.aspx?ItemId=8148bd5e-1436-41db-a4dd-d8da627b7e85)[[4]](https://www.sec.gov/Archives/edgar/data/886163/000088616315000011/lgndfoehrnamedpresident.htm) On January 2, 2026, he sold 16,000 VKTX shares for $561,694 after exercising options, retaining 135,186 shares.[[3]](https://www.investing.com/news/insider-trading-news/viking-therapeutics-director-foehr-sells-561694-in-shares-93CH-4431218)

View full insider profile →

Trade Price

$1.49

Quantity

19,244

Total Value

$28,674.00

Shares Owned

4,420,492

Trade Date

Tuesday, April 7, 2026

2 days ago

SEC Filing Date

Tuesday, April 7, 2026

HEALTHCAREBIOTECHNOLOGY

About Omniab, Inc.

Company Overview

No company information available
View news mentioning OABI

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5450151

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime